// App-Quantinova.ai

198 : QPI-1002, a siRNA Targeting p53: Improvement in Outcomes Following Acute Kidney Injury (AKI): Cardiac Surgery to AKI Donors

Researchers

Presenter

  • J. Tchervenkov

Principal Investigators

  • E. Squiers

  • R. Stratta

  • D. Odenheimer

  • D. Rothenstein

Medical Centers

  • Quark Pharmaceuticals, Fremont

  • McGill University Health Centre, Montreal, QC, Canada

  • Wake Forest School of Medicine, Winston-Salem, NC

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • N/A

Biomarkers

  • p53

Drug/Treatment

  • QPI 1002

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02610296

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved